Patient-reported functional impairment due cisplatin-based hearing loss and tinnitus

A multicenter cross-sectional study evaluated patient-reported functional impairment because of hearing loss (HL) and tinnitus among survivors of cisplatin-treated testicular cancer. HL affected 56.4% and tinnitus affected 60.5% of survivors. Hearing aids were used by 10%. Among the survivors with HL, 35.8% reported clinically significant functional impairment. Survivors with either greater hearing difficulty or more severe tinnitus were more likely to report cognitive dysfunction, fatigue, depression, and worse overall health. The authors conclude that follow-up of cisplatin-treated survivors should include routine assessment for HL and tinnitus.